ExSight Ventures

We are a venture capital firm specializing in early-stage investments in innovative ophthalmic diagnostic and treatment solutions.

[ExSight Ventures @ExsightV]

ExSight partners Firas and James discussing early stage funding of ophthalmic innovation @ OIS Retina with @ONLTherapeutics CEO David Esposito and our friends from InFocus and Outlook Tx.
@OISTWEETS

[Elios @elios_vision]

Dr. @ikekahmed and Professor @gusgazzard kick off the Interventional Glaucoma podcast series as co-hosts with an unscripted discussion about the evolving mindset of interventional glaucoma. They explore the motivations behind this shift, including the need to address the limitations of current treatments, and highlight cataract surgery as an opportune entry point to intervene with simultaneous glaucoma treatment.
Listen now on Apple, Spotify and YouTube.
https://t.co/X2tTCS9Vbt

#EliosVision #Glaucoma #Elios #Excimerlaser #Ophthalmology

https://t.co/h0laPej9a6
ELIOS is not approved for sale in the United States, where it is limited by Federal law to investigational use.

[Elios @elios_vision]

Elios Vision is honored to have Prof. @ikekahmed as co-host for the first episode of the Interventional Glaucoma Podcast.

Professor Ahmed is a world-renowned glaucoma, cataract, and anterior segment surgeon, with a practice focus on the surgical management of glaucoma, complex cataract and intraocular lens complications. He is board certified in ophthalmology in Canada and the USA, and is an active member of numerous national and international societies.

Listen now on Apple, Spotify and YouTube.
https://t.co/X2tTCS9Vbt

#EliosVision #Glaucoma #Elios #Excimerlaser #Ophthalmology

https://t.co/h0laPej9a6
ELIOS is not approved for sale in the United States, where it is limited by Federal law to investigational use.

[ExSight Ventures @ExsightV]

Preserving Sight: ONL Therapeutics' Innovative Approach to Combat Retinal Diseases https://t.co/LJyIiH6kXK via @Clin_Trials @ONLTherapeutics

[ExSight Ventures @ExsightV]

We did a deep dive case study of our investment in DTx Pharma, following their acquisition by Novartis.
https://t.co/oRybUDZun8

[ExSight Ventures @ExsightV]

We've been sharing our excellent experience with Squared Away. This profile of the founder tells a great entrepreneurial journey and speaks to why you should be considering contacting them if you need a personal assistant.

[Squared Away @gosquaredaway]

"Military spouse Michelle Penczak got tired of getting turned down for jobs, so she did something about it. Now she runs a $5 million company that helps women just like her." @michellepencz @kelseyopel & co-founder @ShaneMac

#squaredawaylife #startup

https://t.co/c4bl09Hzdd

[ExSight Ventures @ExsightV]

This is a significant milestone for patients with AMD in a highly dynamic and quickly evolving field.

[Eyewire+ @eyewireplus]

BREAKING: @IvericBio has received FDA approval for #Izervay (avacincaptad pegol intravitreal solution) for the treatment of #geographicatrophy (GA) secondary to age-related macular degeneration (AMD), parent company Astellas Pharma announced Friday night. https://t.co/ypaxong77Y

[ExSight Ventures @ExsightV]

Yosemite is an important model for funding early stage innovation. Focusing on the the early stage while simultaneously funding charitable grants for scientists and labs will raise the quality of startups focused on cancer. 👏
@EmCollective
https://t.co/eUKwqkBFrX

[ExSight Ventures @ExsightV]

Congratulations to the team at DTx Pharma on this amazing achievement!

[ExSight Ventures @ExsightV]

Nice mention of @elios_vision.

[Re-Vana Tx @TxVana]

https://t.co/eoOofhrwua New horizons in interventional glaucoma

[ExSight Ventures @ExsightV]

LPs often ask what we look for in evaluating companies. This response from legendary pharma founder and scientist is spot on: "The most important thing is understanding team dynamics and the difference in personalities that are necessary to build a team and hold it together."

[Angelos Georgakis @angelosgeo]

The founder and former CEO of Vertex Pharmaceuticals, Joshua Boger, was once asked: "What does it take to be a good leader in a pharmaceutical company?"

Boger said, "Pharmaceutical discovery and development is the most complicated activity that humans do.

Going to Mars is easy, going to Mars is engineering! I mean, I'm not an engineer but if you give me a hundred billion dollars, I guarantee you I can put you on Mars. There's nothing stopping me except organisational momentum and money.

But if you give me a hundred billion dollars and say, in five years or ten years you have to cure Alzheimer's disease... I'll say... I'll give it a go but I have no idea whether I could do it!

Drug discovery and development is just an insanely complicated activity to do that you need to keep teams of people together for a very long time.

And this is what distinguishes it from most of the high-tech, ie. I have a high-tech idea, I should be shipping it in 18 months. If I have a pharmaceutical idea I may be shipping it in 18 years!

So I need to keep a team of people together on the discovery and development side for 12 to 15 years on average.

The most important thing is understanding team dynamics and the difference in personalities that are necessary to build a team and hold it together. To do that, you the leader have to be incredibly passionate about what you're trying to do. It's a combination of empathy and passion...

And you have to lead by example. Very often I was the last person to cut the lights out at midnight or 1 am. And it's not just the number of hours... the people who report to you can see you, and they can tell whether or not you're thinking about the mission all the time..."

[Elios @elios_vision]

Check out our highlights from Day 1 at the WGC! It has been great connecting with everyone. Bring on Day 2!
#WGC #Elios
https://t.co/oeklNBkWaA
ELIOS is not approved for sale in the United States, where it is limited by Federal law to investigational use.

[ExSight Ventures @ExsightV]

Diabetes is a primary cause of vision loss. There is plenty of room for innovation as this population explodes.
https://t.co/PfvsWPKxb0

[ExSight Ventures @ExsightV]

Roman Holiday - @elios_vision heads to the eternal city for the World Glaucoma Congress.

[Elios @elios_vision]

We are attending the WGC on 28th June – 1st July. Join us at our booth and look out for our ‘What the hELIOS’ symposium!

#WGC #Elios

https://t.co/oeklNBkWaA
ELIOS is not approved for sale in the United States, where it is limited by Federal law to investigational use.

[BowTiedBiotech 🧪🔬🧬 @BowTiedBiotech]

May #Biotech Hedge Fund Performance

RA Cap +7.8% (+1.2% YTD)
Casdin +4.7% (+10.7% YTD)
Soleus +4.4% (+3.4% YTD)
Perceptive +2.4% (+8.4% YTD)
RTW +1.8% (+6.4% YTD)
Averill +1.5% (+2.6% YTD)

XBI +3% (+5.6% YTD)

[ASCRS @ASCRStweets]

Cataract misconception: Cataract surgery is an “easy” procedure. Learn more https://t.co/vjBDIGyoWY #CataractAwareness

[Brian McCaul @brianamc]

In Northern Ireland there were also five deals in 2022 into life sciences, one of which was valued at £9.9m into Re-Vana Tx @TxVana, a spin-out from Queen’s University which is developing technologies for photocrosslinking for ocular drug delivery @QubisLtd

[lensgeninc @lensgeninc]

Sumit Garg, M.D. Presented Thirty-Six Months Grail Study Visual Outcomes at the American Society of Cataract and Refractive Surgery Conference

https://t.co/mzUeNwdOsC

[ExSight Ventures @ExsightV]

ExSight portfolio company @TrefoilThera was featured in their hometown San Diego Business Journal
“We’re happy because the drug works. We demonstrated that it works.” - David Eveleth
Read the article here: https://t.co/peSwDhYxMW
@SDbusiness

[ExSight Ventures @ExsightV]

For Clinical Trials Day 2023 @ONLTherapeutics hosted investigators of their Ph 2 clinical trial studying ONL1204 Ophthalmic Solution in retinal detachment patients.
Thank you to all participating clinicians, research staff, and patients.
https://t.co/ub0z5BKkmB

[ExSight Ventures @ExsightV]

Ophthalmic Drug Market is estimated to be US$ 132.06 billion by 2030 with a CAGR of 4.30% during the forecast period
https://t.co/0HUjpA0Tj1